Michael Hofman
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
Michael Hofman's randomised trials at Peter Mac established PSMA PET/CT for staging prostate cancer and 177Lu-PSMA-617 as an effective therapy, making Australia a global centre of theranostics; he now leads trials of earlier-line and combination radioligand therapy.
Pages like this
not linked directly; found by shared links- PersonShahneen Sandhu
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, Lutetium-177 vipivotide tetraxetan, PSMA.
- PersonRahul Aggarwal
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonUwe Haberkorn
Shares A university cyclotron network with shared regulatory files for new tracers, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- PersonMichael J. Morris
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- CollectionProstate Cancer Foundation (PCF)
Shares Movember, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- CompanyClarity Pharmaceuticals
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJeremie Calais
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.